Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
antimiR-708
- Development stage
- Preclinical
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
antimiR-708 is an antisense oligonucleotide (ASO) designed to specifically bind to and inhibit the activity of microRNA-708 (miR-708). In the context of muscular dystrophies such as Duchenne (DMD) and Becker (BMD), miR-708-5p has been identified as a negative regulator of neuronal nitric oxide synthase (nNOS) expression. By sequestering miR-708, antimiR-708 aims to prevent the degradation or translational repression of nNOS mRNA, thereby restoring nNOS protein levels and improving muscle function and fatigability. Beyond muscular dystrophy, miR-708 inhibition is also explored in various cancers and ocular diseases where the microRNA is aberrantly expressed and contributes to disease progression or endoplasmic reticulum (ER) stress.
- Other names
- microRNA-708 inhibitormicroRNA708 inhibitormicroRNA 708 inhibitorhsa-miR-708-5p inhibitorhsa-miR708-5p inhibitorhsa-miR 708-5p inhibitor
Beyond the preview
Go deeper on antimiR-708.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on antimiR-708.